DE69834038D1 - Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre - Google Patents
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhreInfo
- Publication number
- DE69834038D1 DE69834038D1 DE69834038T DE69834038T DE69834038D1 DE 69834038 D1 DE69834038 D1 DE 69834038D1 DE 69834038 T DE69834038 T DE 69834038T DE 69834038 T DE69834038 T DE 69834038T DE 69834038 D1 DE69834038 D1 DE 69834038D1
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotides
- compositions
- administration
- animal
- nucleic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88682997A | 1997-07-01 | 1997-07-01 | |
PCT/US1998/013574 WO1999001579A1 (en) | 1997-07-01 | 1998-07-01 | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69834038D1 true DE69834038D1 (de) | 2006-05-18 |
Family
ID=25389866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69834038T Expired - Lifetime DE69834038D1 (de) | 1997-07-01 | 1998-07-01 | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
Country Status (8)
Country | Link |
---|---|
US (4) | US6887906B1 (de) |
EP (1) | EP1012331B1 (de) |
JP (1) | JP2002510319A (de) |
AT (1) | ATE321882T1 (de) |
AU (1) | AU731909B2 (de) |
CA (1) | CA2294988C (de) |
DE (1) | DE69834038D1 (de) |
WO (1) | WO1999001579A1 (de) |
Families Citing this family (335)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7235653B2 (en) | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
AU745880B2 (en) | 1998-05-21 | 2002-04-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
WO1999060167A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
CA2689696C (en) * | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2000067798A2 (en) * | 1999-05-05 | 2000-11-16 | Elan Corporation Plc | Enhanced delivery of nucleic acid-based drugs |
US20080281041A1 (en) * | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
US8541548B2 (en) * | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
US20030036520A1 (en) * | 1999-07-23 | 2003-02-20 | Jack Gauldie | Intestinal gene therapy |
WO2001048231A2 (en) * | 1999-12-28 | 2001-07-05 | Novartis Ag | Method of achieving persistent transgene expression |
EP1118333A1 (de) * | 2000-01-18 | 2001-07-25 | Eurand International S.P.A. | Zusammensetzungen mit erhöhter oraler Bioverfügbarkeit |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
PT1362600E (pt) * | 2001-02-20 | 2008-07-09 | Anges Mg Inc | Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica |
CA2447444A1 (en) | 2001-05-11 | 2002-11-21 | Orasense, Ltd. | Antisense permeation enhancers |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
AU2002363182A1 (en) * | 2001-11-02 | 2003-05-12 | Ribopharma Ag | Smad7 inhibitors for the treatment of cns diseases |
WO2003074108A2 (en) * | 2002-02-28 | 2003-09-12 | Mayo Foundation For Medical Education And Research | Compositions for generating submucosal fluid cushions |
WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
JP4796303B2 (ja) * | 2002-12-12 | 2011-10-19 | ノバルティス アーゲー | 4−ヒドロキシ−プロリン部分構造を含むペプチドの合成方法 |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
CN101273051B (zh) * | 2003-04-13 | 2012-04-18 | 安龙制药公司 | 聚合寡核苷酸前体药物 |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
WO2004100966A1 (ja) | 2003-05-16 | 2004-11-25 | Bbk Bio Corporation | 病態起因物質の生体への接触防止用製剤 |
WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2005000202A2 (en) * | 2003-05-23 | 2005-01-06 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of b7 protein |
US7897582B2 (en) | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7960355B2 (en) | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
WO2005038013A1 (en) * | 2003-10-07 | 2005-04-28 | Isis Pharmaceuticals, Inc. | Artisense oligonucleotides optimized for kidney targeting |
US20050191653A1 (en) * | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
FR2862235B1 (fr) * | 2003-11-13 | 2007-12-28 | Rhodia Chimie Sa | Emulsion pour vehiculer une matiere active hydrophobe vers un substrat en milieu aqueux |
US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP1737878A2 (de) * | 2004-04-05 | 2007-01-03 | Alnylam Pharmaceuticals Inc. | Verfahren und reagentien für die synthese und aufreinigung von oligonukleotiden |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
CA2738682A1 (en) | 2004-04-15 | 2005-10-15 | Eng-Hong Lee | Soft gel delivery system for treating poultry |
JP2008501335A (ja) * | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク. | キメラギャップ化オリゴマー組成物 |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
JP2008501693A (ja) * | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク. | 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物 |
US7582744B2 (en) * | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
US20060046969A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
US20090047347A1 (en) * | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
US8642564B2 (en) * | 2004-08-25 | 2014-02-04 | Aegis Therapeutics, Llc | Compositions for drug administration |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US9114069B2 (en) * | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
JP2008513513A (ja) * | 2004-09-21 | 2008-05-01 | アネシヴァ, インコーポレイテッド | ポリヌクレオチドの送達 |
MX2007006591A (es) * | 2004-12-02 | 2008-03-04 | Isis Pharmaceuticals Inc | Composici??n terap??utica de oligonucle??tidos de antisentido para el tratamiento de la enfermedad intestinal inflamatoria. |
US20060240108A1 (en) * | 2005-04-26 | 2006-10-26 | Bernard Bobby L | Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability |
GT200600405A (es) * | 2005-09-07 | 2007-04-16 | Formula de microemulsión | |
EP1764107A1 (de) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Zusammensetzungen enthaltend immunstimulierende RNA-Oligonukleotide und Methoden zu deren Herstellung |
US20070197460A1 (en) * | 2005-11-01 | 2007-08-23 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7807652B2 (en) | 2005-11-21 | 2010-10-05 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US8229398B2 (en) * | 2006-01-30 | 2012-07-24 | Qualcomm Incorporated | GSM authentication in a CDMA network |
JP5450052B2 (ja) | 2006-04-07 | 2014-03-26 | メリオン リサーチ Iii リミテッド | 強化剤を含む固体経口投与剤形 |
AU2007245599B2 (en) * | 2006-05-03 | 2012-05-10 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
WO2007137156A2 (en) * | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
US20090209625A1 (en) * | 2006-05-23 | 2009-08-20 | Sanjay Bhanot | Modulation of chrebp expression |
JP2009539862A (ja) * | 2006-06-09 | 2009-11-19 | メリオン リサーチ Iii リミテッド | 強化剤を含む固体経口投与剤形 |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
US8017109B2 (en) * | 2006-08-18 | 2011-09-13 | Roche Madison Inc. | Endosomolytic poly(acrylate) polymers |
CA2660842C (en) * | 2006-08-18 | 2012-03-13 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
US8110559B2 (en) * | 2006-09-15 | 2012-02-07 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
KR20090083334A (ko) * | 2006-09-15 | 2009-08-03 | 엔존 파마슈티컬즈, 인코포레이티드 | 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드 |
CA2662978A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
EP2120966A4 (de) * | 2006-11-27 | 2013-06-19 | Enzon Pharmaceuticals Inc | Polymere konjugate mit kurzer interferierender rna |
US8048998B2 (en) * | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
US20100280098A1 (en) * | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
MX2010004984A (es) * | 2007-11-05 | 2010-07-29 | Baltic Technology Dev Ltd | Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos. |
US7834172B2 (en) * | 2007-11-14 | 2010-11-16 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC |
AU2008342535B2 (en) | 2007-12-27 | 2015-02-05 | Arbutus Biopharma Corporation | Silencing of polo-like kinase expression using interfering RNA |
EP2712926A2 (de) | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5- und des VEGF-Gens |
EP2105145A1 (de) | 2008-03-27 | 2009-09-30 | ETH Zürich | Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide |
CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
EP2770057A1 (de) | 2008-04-15 | 2014-08-27 | Protiva Biotherapeutics Inc. | Stilllegung von CSN5-Genexpression mittels interferierender RNA |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
EP2288369B1 (de) * | 2008-05-07 | 2014-07-09 | Merrion Research III Limited | Zusammensetzungen von gnrh-verwandten verbindungen und herstellungsverfahren |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
WO2010017509A1 (en) * | 2008-08-07 | 2010-02-11 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
EP2690175B1 (de) | 2008-09-02 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6 |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
JP5529142B2 (ja) | 2008-09-25 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法 |
SI2937418T1 (en) | 2008-10-20 | 2018-02-28 | Alnylam Pharmaceuticals, Inc. | Compounds and procedures for inhibiting the expression of transthyretin |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
US20100222417A1 (en) * | 2008-11-26 | 2010-09-02 | Alnylam Pharmaceuticals | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues |
JP5855462B2 (ja) | 2008-12-10 | 2016-02-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | GNAQを標的としたdsRNA組成物および発現を阻害するための方法 |
US8440631B2 (en) * | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
US9012225B2 (en) | 2009-05-05 | 2015-04-21 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
EP2429503A1 (de) * | 2009-05-13 | 2012-03-21 | Protein Delivery Solutions, LLC | Pharmazeutisches system zur transmembranösen abgabe |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
EP2488210A4 (de) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis |
US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
EP2509953B1 (de) | 2009-12-11 | 2016-03-30 | Genecode AS | Verfahren für das überleben von nervenzellen mit ligandenmimetika der gdnf-familie oder aktivatoren des ret-signalweges |
CA2784120A1 (en) | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
AP3284A (en) * | 2010-02-24 | 2015-05-31 | Arrowhead Res Corp | Compositions for targeted delivery of SIRNA |
EP2550000A4 (de) | 2010-03-24 | 2014-03-26 | Advirna Inc | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
ES2893199T3 (es) | 2010-03-29 | 2022-02-08 | Alnylam Pharmaceuticals Inc | Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR) |
JP5058351B2 (ja) * | 2010-04-13 | 2012-10-24 | 株式会社 資生堂 | 水中油型乳化組成物 |
BR112012027547B1 (pt) | 2010-04-29 | 2022-06-14 | Ionis Pharmaceuticals, Inc | Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina |
JP6081910B2 (ja) | 2010-06-02 | 2017-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 肝線維症治療用組成物および肝線維症の治療法 |
CA2802994A1 (en) | 2010-06-17 | 2011-12-22 | The United States Of America As Represented By The Secretary, National I Nstitutes Of Health | Compositions and methods for treating inflammatory conditions |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103179988B (zh) * | 2010-08-20 | 2016-02-24 | 国立大学法人东京医科齿科大学 | 经大肠吸收用药物组合物 |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
JP2012111933A (ja) * | 2010-11-02 | 2012-06-14 | Nitto Denko Corp | 熱可塑性シリコーン樹脂 |
CA2817002C (en) | 2010-11-05 | 2019-01-15 | Miragen Therapeutics | Base modified oligonucleotides |
WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
EP2648763A4 (de) | 2010-12-10 | 2014-05-14 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a |
CN103380215A (zh) | 2010-12-15 | 2013-10-30 | 米拉根医疗公司 | 包含锁定核苷酸的微rna抑制剂 |
EP2661273A4 (de) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung |
WO2012106490A1 (en) | 2011-02-03 | 2012-08-09 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
KR102104401B1 (ko) | 2011-03-29 | 2020-04-27 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP3159410A2 (de) | 2011-04-12 | 2017-04-26 | Beth Israel Deaconess Medical Center, Inc. | Mikro-rna-inhibitoren und ihre verwendung bei erkrankungen |
JP6662566B2 (ja) | 2011-06-02 | 2020-03-11 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | エキソビボ組織培養システムのための方法および使用 |
WO2012174158A2 (en) | 2011-06-14 | 2012-12-20 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
AU2012272908A1 (en) | 2011-06-21 | 2013-12-19 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
RU2631805C2 (ru) | 2011-06-21 | 2017-09-26 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3) |
EP3388068A1 (de) | 2011-06-21 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen |
AU2012272970A1 (en) | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
AU2012275841A1 (en) | 2011-06-27 | 2014-01-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
JP2014526887A (ja) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 造血幹細胞移植の成功率を改善する方法 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2844577A1 (en) | 2011-09-13 | 2013-03-21 | Ottawa Hospital Research Institute | Microrna inhibitors |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
CA2856116A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
BR112014021065A8 (pt) | 2012-02-21 | 2018-04-24 | Centre Nat Rech Scient | receptores tam como cofatores de entrada do vírus |
EP2817327A1 (de) | 2012-02-21 | 2014-12-31 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Tim-rezeptoren als viruseintrittskofaktoren |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
GB201209895D0 (en) | 2012-06-01 | 2012-07-18 | Atlantic Pharmaceuticals Holdings Ltd | Use of a composition |
EP2864482A4 (de) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | Oligonukleotidbasierte inhibitoren mit blockiertem nukleinsäuremotiv |
WO2014016152A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
MX2015003643A (es) | 2012-09-21 | 2016-04-06 | Intensity Therapeutics Inc | Metodo para tratar el cancer. |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
CN104854242B (zh) | 2012-12-05 | 2018-03-16 | 阿尔尼拉姆医药品有限公司 | PCSK9 iRNA组合物及其使用方法 |
PT2953934T (pt) | 2013-02-08 | 2018-05-08 | Gen Mills Inc | Produtos alimentares com baixo teor de sódio |
CN114015692A (zh) | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP6446026B2 (ja) | 2013-03-15 | 2018-12-26 | ミラゲン セラピューティクス, インコーポレイテッド | 架橋二環式ヌクレオシド |
WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
HUE038146T2 (hu) | 2013-05-22 | 2018-09-28 | Alnylam Pharmaceuticals Inc | Serpina1 IRNS készítmények és eljárások alkalmazásukra |
EP2999786A1 (de) | 2013-05-22 | 2016-03-30 | Alnylam Pharmaceuticals, Inc. | Tmprss6-irna-zusammensetzungen und verfahren zur verwendung davon |
US10036020B2 (en) | 2013-09-19 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting JC virus (JCV) |
CN105793423A (zh) | 2013-10-02 | 2016-07-20 | 阿尔尼拉姆医药品有限公司 | 用于抑制lect2基因表达的组合物和方法 |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
NZ757749A (en) | 2013-10-04 | 2022-07-01 | Icahn School Med Mount Sinai | Compositions and methods for inhibiting expression of the alas1 gene |
EP3068783B1 (de) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen |
WO2015074010A2 (en) | 2013-11-18 | 2015-05-21 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
CA3107872A1 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
EA201691587A1 (ru) | 2014-02-11 | 2017-01-30 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
GB201407822D0 (en) | 2014-05-02 | 2014-06-18 | Atlantic Pharmaceuticals Holdings Ltd | Use of a composition |
WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
SG11201609376SA (en) | 2014-05-22 | 2016-12-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
CN108064175A (zh) | 2014-08-04 | 2018-05-22 | 米拉根医疗股份有限公司 | Myh7b的抑制剂及其用途 |
BR112017004648A2 (pt) | 2014-09-08 | 2018-05-08 | Miragen Therapeutics Inc | simuladores mir-29 e os usos deste |
EP3191591A1 (de) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon |
US10415037B2 (en) | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
EP3207138B1 (de) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon |
EP3212794B1 (de) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
AU2015364508A1 (en) | 2014-12-18 | 2017-07-06 | Alnylam Pharmaceuticals, Inc. | ReversirTM compounds |
EP3247386A4 (de) | 2015-01-20 | 2018-10-03 | The Children's Medical Center Corporation | Anti-net-verbindungen zur behandlung und prävention von fibrose und wundheilungsförderung |
WO2016118612A2 (en) | 2015-01-20 | 2016-07-28 | MiRagen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
CN209264567U (zh) | 2015-04-09 | 2019-08-16 | 必康达 | 使用荧光纳米金刚石的成像系统 |
EP3294889B1 (de) | 2015-05-11 | 2021-01-06 | Murdoch University | Behandlung von multipler sklerose |
WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
WO2016197024A2 (en) | 2015-06-05 | 2016-12-08 | MiRagen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
EP3307316A1 (de) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
JP2018520683A (ja) | 2015-07-17 | 2018-08-02 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 多標的単一体コンジュゲート |
CN108350455A (zh) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
EP3344769B1 (de) | 2015-09-02 | 2024-04-17 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (pd-l1) irna-kompositionen und methoden zu deren verwendung |
JP6875685B2 (ja) * | 2015-10-08 | 2021-05-26 | 日油株式会社 | O/w型エマルション |
CN109563509B (zh) | 2015-10-19 | 2022-08-09 | 菲奥医药公司 | 靶向长非编码rna的减小尺寸的自递送核酸化合物 |
WO2017087486A1 (en) | 2015-11-16 | 2017-05-26 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein |
SG11201806868TA (en) | 2016-02-25 | 2018-09-27 | Applied Biological Laboratories Inc | Compositions and methods for protecting against airborne pathogens and irritants |
US20170360815A1 (en) | 2016-02-25 | 2017-12-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
EP4104854A3 (de) | 2016-04-04 | 2023-03-08 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Multivalente impfstoffe gegen tollwutvirus und coronaviren |
MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
MA45290A (fr) * | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
ES2659845B1 (es) | 2016-09-19 | 2019-01-04 | Univ Valencia | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
US20180179542A1 (en) | 2016-11-11 | 2018-06-28 | Alios Biopharma, Inc. | OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA |
US20190070109A1 (en) * | 2016-11-18 | 2019-03-07 | National Tsing Hua University | Pharmaceutical composition for oral delivery |
TW201818926A (zh) * | 2016-11-18 | 2018-06-01 | 國立清華大學 | 醫藥組合物 |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
GB201700257D0 (en) * | 2017-01-06 | 2017-02-22 | Atlantic Pharmaceuticals (Holdings) Ltd | New formulation |
EP3577224A4 (de) | 2017-02-03 | 2020-11-25 | The University Of Western Australia | Neuartige behandlung von neat1-assoziierten erkrankungen |
BR112019021852A2 (pt) | 2017-04-18 | 2020-06-02 | Alnylam Pharmaceuticals, Inc. | Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento |
CA3061752A1 (en) | 2017-07-06 | 2019-01-10 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of alpha-enac and methods of use |
EP3652317A1 (de) | 2017-07-13 | 2020-05-20 | Alnylam Pharmaceuticals, Inc. | Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung |
US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
CA3078971A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
WO2019099610A1 (en) | 2017-11-16 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
EP3714054A1 (de) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung |
EP3713603A1 (de) | 2017-11-23 | 2020-09-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Neues verfahren zur behandlung einer dengue-virus-infektion |
AR113490A1 (es) | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
KR20200100083A (ko) | 2017-12-15 | 2020-08-25 | 디 오스트레일리언 내셔널 유니버시티 | 세포외 히스톤 매개된 병리를 치료 및 예방하기 위한 화합물 |
CA3086343A1 (en) | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
EP3728295A1 (de) | 2017-12-20 | 2020-10-28 | Allergan, Inc. | Botulinumtoxin-zellbindungsdomänen-polypeptide und verfahren zur verwendung für behandlungen von fibrose-assoziierten erkrankungen |
CA3086479A1 (en) | 2017-12-21 | 2019-06-27 | Carnegie Mellon University | Template-directed nucleic acid targeting compounds |
PT3514235T (pt) * | 2018-01-18 | 2024-02-12 | Sterna Biologicals Gmbh | Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento |
US11753639B2 (en) | 2018-03-14 | 2023-09-12 | Beth Israel Deaconess Medical Center | Micro-RNA and obesity |
EP3837367A1 (de) | 2018-08-16 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der lect2-genexpression |
US20210332367A1 (en) | 2018-09-18 | 2021-10-28 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
AU2019395341A1 (en) | 2018-12-10 | 2021-06-17 | Amgen Inc. | Chemically-modified RNAi constructs and uses thereof |
BR112021011061A2 (pt) | 2018-12-10 | 2021-08-31 | Amgen Inc. | Construtos de rnai para inibir a expressão de pnpla3 |
EP4285929A3 (de) | 2018-12-20 | 2024-03-06 | Humabs Biomed SA | Kombinierte hbv-therapie |
MX2021013858A (es) | 2019-05-14 | 2022-03-22 | Univ Monash | Moduladores y modulación del arn de receptor para productos finales de glicación avanzada. |
TW202111124A (zh) | 2019-05-30 | 2021-03-16 | 美商安進公司 | 用於抑制scap表現之rnai構建體及其使用方法 |
EP4013871A1 (de) | 2019-08-13 | 2022-06-22 | Amgen Inc. | Rnai-konstrukte zur hemmung der slc30a8-expression und verfahren zur verwendung davon |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
EP4025694A1 (de) | 2019-09-03 | 2022-07-13 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zum hemmen der lect2-genexpression |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021072139A1 (en) | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
AR120341A1 (es) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
EP4061945A1 (de) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung |
MX2022007005A (es) | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
WO2021119226A1 (en) | 2019-12-13 | 2021-06-17 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
TW202204615A (zh) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | 冠狀病毒iRNA組成物及其使用方法 |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
EP4133078A1 (de) | 2020-04-06 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur ausschaltung der myoc-expression |
TW202204617A (zh) | 2020-04-07 | 2022-02-01 | 美商艾爾妮蘭製藥公司 | 用於靜默scn9a表現之組合物及方法 |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
EP4133076A1 (de) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon |
EP4143319A1 (de) | 2020-04-27 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon |
WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
EP4150076A1 (de) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
US20230088509A1 (en) | 2020-05-20 | 2023-03-23 | St. Jude Children's Research Hospital | Detection of alzheimer's disease using specific biomarkers |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
IL298697A (en) | 2020-06-01 | 2023-02-01 | Amgen Inc | RNA interference constructs to inhibit hsd17b13 expression and methods for using them |
EP4162050A1 (de) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation |
KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
EP3929295A1 (de) | 2020-06-26 | 2021-12-29 | Universitat Pompeu Fabra | Künstliche rnas zur modulation von rna-fragmenten |
AU2021326521A1 (en) | 2020-08-13 | 2023-03-09 | Amgen Inc. | RNAi constructs and methods for inhibiting MARC1 expression |
EP4217489A1 (de) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon |
JP2023544413A (ja) | 2020-10-05 | 2023-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法 |
EP4232581A1 (de) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie |
EP4232582A1 (de) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon |
CA3199678A1 (en) | 2020-11-05 | 2022-05-12 | Amgen Inc. | Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs |
EP4256053A1 (de) | 2020-12-01 | 2023-10-11 | Alnylam Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression |
CA3210763A1 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
EP4298220A1 (de) | 2021-02-25 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon |
EP4305169A1 (de) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon |
KR20230162024A (ko) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | 헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법 |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
EP4341405A1 (de) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Verfahren und zusammensetzungen für adar-vermittelte bearbeitung |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
AR126000A1 (es) | 2021-06-04 | 2023-08-30 | Alnylam Pharmaceuticals Inc | Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos |
EP4351541A2 (de) | 2021-06-08 | 2024-04-17 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4) |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
KR20240037293A (ko) | 2021-07-23 | 2024-03-21 | 알닐람 파마슈티칼스 인코포레이티드 | 베타-카테닌(CTNNB1) iRNA 조성물 및 이의 사용 방법 |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
AU2022323090A1 (en) | 2021-08-03 | 2024-02-01 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
WO2023014765A1 (en) | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) |
TW202334413A (zh) | 2021-08-13 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 第十二因子(F12)iRNA組成物及其使用方法 |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
CA3232420A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
CA3234369A1 (en) | 2021-10-05 | 2023-04-13 | Amagen, Inc. | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
CA3234835A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023069754A2 (en) | 2021-10-22 | 2023-04-27 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023144163A1 (en) | 2022-01-25 | 2023-08-03 | Albert-Ludwigs-Universität Freiburg | A glun2d inhibitor for use in the treatment or relapse prevention of a depressive episode |
WO2023177870A1 (en) | 2022-03-18 | 2023-09-21 | Baylor College Of Medicine | Potentiation of durable antitumor immunity by multifactorial immune modulation |
WO2023183556A2 (en) * | 2022-03-24 | 2023-09-28 | Amcyte Pharma, Inc. | Treatment for retinal disorders |
US20240084301A1 (en) | 2022-07-25 | 2024-03-14 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
EP4353823A1 (de) | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitoren von mikro-rna 22 |
Family Cites Families (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA218654A (en) | 1922-05-16 | The Canadian Westinghouse Company | Heat regulating attachment for tube machines | |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
AR205589A1 (es) | 1974-10-09 | 1976-05-14 | Reckitt & Colmann Prod Ltd | Dispositivo introductor de una composicion acuosa en una cavidad corporal |
JPS5780314U (de) | 1980-11-04 | 1982-05-18 | ||
JPS5780314A (en) * | 1980-11-09 | 1982-05-19 | Kyoto Yakuhin Kogyo Kk | Pharmaceutical preparation to be medicated to rectum |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
NZ209840A (en) | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5298614A (en) | 1986-01-06 | 1994-03-29 | Nippon Shinyaku Co. Ltd. | Size limited double stranded poly I poly(cytidylate/4-thiouridylate) |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
US4878979A (en) | 1986-04-25 | 1989-11-07 | United Technologies Corporation | Method of reusably sealing a silicone rubber vacuum bag to a mold for composite manufacture |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
DE3788914T2 (de) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
AU598946B2 (en) | 1987-06-24 | 1990-07-05 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
DE3855864T2 (de) | 1987-11-30 | 1997-09-25 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US5543508A (en) | 1987-12-15 | 1996-08-06 | Gene Shears Pty. Limited | Ribozymes |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
DK0497875T3 (da) | 1989-10-24 | 2000-07-03 | Gilead Sciences Inc | 2'-modificerede oligonukleotider |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5223168A (en) | 1989-12-12 | 1993-06-29 | Gary Holt | Surface cleaner and treatment |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5591623A (en) | 1990-08-14 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5506351A (en) | 1992-07-23 | 1996-04-09 | Isis Pharmaceuticals | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5955589A (en) | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
WO1992002258A1 (en) | 1990-07-27 | 1992-02-20 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
DK0541722T3 (da) | 1990-08-03 | 1996-04-22 | Sterling Winthrop Inc | Forbindelser og fremgangsmåder til inhibering af genekspression |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
US5843738A (en) * | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
US6111094A (en) | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5595978A (en) | 1990-08-16 | 1997-01-21 | Isis Pharmaceuticals, Inc. | Composition and method for treatment of CMV retinites |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
WO1992008728A1 (en) | 1990-11-08 | 1992-05-29 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US5674530A (en) | 1991-01-31 | 1997-10-07 | Port Systems, L.L.C. | Method for making a multi-stage drug delivery system |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5242906A (en) | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
WO1992020813A1 (en) | 1991-05-17 | 1992-11-26 | Dana Farber Cancer Institute | Assays for factors affecting circularization of dna, assays for factors affecting dna integration, factors, and uses thereof |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
WO1992021353A1 (en) | 1991-05-31 | 1992-12-10 | Genta Incorporated | Compositions and delivery systems for transdermal administration of neutral oligomers |
DE69225227T2 (de) | 1991-06-27 | 1998-10-29 | Genelabs Tech Inc | Screeningtest für den nachweis von dna-bindenden molekülen |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
JPH07502339A (ja) | 1991-07-25 | 1995-03-09 | ザ ホイッタカー コーポレイション | 液位センサ |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5338837A (en) | 1991-12-13 | 1994-08-16 | The Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making same |
US5780444A (en) | 1991-12-13 | 1998-07-14 | Trustees Of Princeton University | Compositions and methods for cell transformation |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
AU3972893A (en) * | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
RU95104940A (ru) | 1992-07-27 | 1997-01-10 | Хайбрайдон | Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения |
EP0662003B1 (de) | 1992-09-02 | 2003-01-29 | Isis Pharmaceuticals, Inc. | Beeinflussing der zelladhäsie durch oligonukleotide |
CA2105595A1 (en) | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
KR960701077A (ko) | 1993-01-25 | 1996-02-24 | 다알렌 반스톤 | 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates) |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
ATE187713T1 (de) | 1993-02-19 | 2000-01-15 | Nippon Shinyaku Co Ltd | Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung |
JPH08506961A (ja) | 1993-02-19 | 1996-07-30 | ジンタ・インコーポレイテッド | アンチセンスオリゴマー類を使用するアンドロゲン関連禿頭症の治療 |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
GB9304620D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Compounds |
ES2107205T3 (es) | 1993-03-30 | 1997-11-16 | Sanofi Sa | Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen. |
CA2159629A1 (en) | 1993-03-31 | 1994-10-13 | Sanofi | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
EP0804174A4 (de) | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | Mehrkammerhartkapseln mit kontrollierten abgabeeigenschaften |
US5571902A (en) | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
CA2170869C (en) | 1993-09-03 | 1999-09-14 | Phillip Dan Cook | Amine-derivatized nucleosides and oligonucleosides |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
CA2176927C (en) * | 1993-11-17 | 2010-03-23 | Seang H. Yiv | Transparent liquid for encapsulated drug delivery |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
ES2149962T3 (es) | 1993-12-09 | 2000-11-16 | Univ Jefferson | Compuestos y metodos para mutaciones dirigidas al sitio en celulas eucarioticas. |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5641754A (en) * | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5554746A (en) | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
JPH07330614A (ja) | 1994-06-02 | 1995-12-19 | L T T Kenkyusho:Kk | 遺伝子の細胞内導入用脂肪乳剤 |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5545729A (en) | 1994-12-22 | 1996-08-13 | Hybridon, Inc. | Stabilized ribozyme analogs |
WO1996030051A1 (en) | 1995-03-31 | 1996-10-03 | Genetic Therapy, Inc. | Use of surfactants for introducing genetic material into lung cells |
US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
FR2733500B1 (fr) | 1995-04-28 | 1997-07-25 | Centre Nat Rech Scient | Nouveaux antisens diriges contre ras, preparation et utilisations |
US5955059A (en) | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
AU6097896A (en) | 1995-06-07 | 1996-12-30 | Alza Corporation | Oral delivery of gene constructs |
HUP9900910A2 (hu) | 1995-06-07 | 1999-07-28 | Lynx Therapeutics, Inc. | Oligonukleotid jelzések osztályozáshoz és azonosításhoz |
GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US5994062A (en) * | 1995-10-02 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial protein and DNA thereof for use in early cancer detection |
EP0854937B9 (de) | 1995-10-06 | 2006-06-28 | Perseptive Biosystems, Inc. | Verfahren und testsystem zur hybridisierungsanalyse unter verwendung von peptidnukleinsäure-sonden |
CA2231273A1 (en) | 1995-10-12 | 1997-04-17 | Lise Sylvest Nielsen | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
US5846525A (en) * | 1995-12-19 | 1998-12-08 | Trega Biosciences, Inc. | Protected biopolymers for oral administration and methods of using same |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US5980861A (en) * | 1996-03-12 | 1999-11-09 | University Of Massachusetts | Chelator compositions and methods of synthesis thereof |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
US5994319A (en) | 1996-04-15 | 1999-11-30 | Dyad Pharmaceutical Corporation | Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
CA2259179C (en) | 1996-07-03 | 2008-09-23 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
GB9619894D0 (en) | 1996-09-24 | 1996-11-06 | Celltech Therapeutics Ltd | Pharmaceutical products |
KR19980067138A (ko) | 1997-01-31 | 1998-10-15 | 박원훈 | 유전자 또는 생물학적 활성 약물을 세포내로 효과적으로 전달하는 지방 유제 및 그것의 제조방법 |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
KR20010020370A (ko) | 1997-04-30 | 2001-03-15 | 파샬 비. 린네 | 향상된 생체이용률을 갖는 올리고뉴클레오티드 |
ATE321882T1 (de) * | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
WO1999007342A1 (en) | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
ES2224428T3 (es) | 1997-09-26 | 2005-03-01 | Celltech Pharma Europe Limited | Composicion farmnaceutica para el tratamiento de la enfermedad inflmatoria intestinal. |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
AU745880B2 (en) | 1998-05-21 | 2002-04-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
WO1999060167A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6080580A (en) * | 1998-10-05 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression |
US6133031A (en) * | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
US6008048A (en) * | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
US6159694A (en) * | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
US6037176A (en) * | 1999-06-25 | 2000-03-14 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin beta 3 expression |
US6610674B1 (en) * | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
-
1998
- 1998-07-01 AT AT98934207T patent/ATE321882T1/de not_active IP Right Cessation
- 1998-07-01 US US09/108,673 patent/US6887906B1/en not_active Expired - Lifetime
- 1998-07-01 AU AU83786/98A patent/AU731909B2/en not_active Expired
- 1998-07-01 DE DE69834038T patent/DE69834038D1/de not_active Expired - Lifetime
- 1998-07-01 JP JP50729599A patent/JP2002510319A/ja not_active Withdrawn
- 1998-07-01 EP EP98934207A patent/EP1012331B1/de not_active Expired - Lifetime
- 1998-07-01 WO PCT/US1998/013574 patent/WO1999001579A1/en active IP Right Grant
- 1998-07-01 CA CA2294988A patent/CA2294988C/en not_active Expired - Lifetime
-
2001
- 2001-12-21 US US10/029,598 patent/US6747014B2/en not_active Expired - Fee Related
-
2004
- 2004-03-04 US US10/793,497 patent/US20040229831A1/en not_active Abandoned
-
2013
- 2013-01-07 US US13/735,229 patent/US8691785B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2294988C (en) | 2015-11-24 |
EP1012331A1 (de) | 2000-06-28 |
WO1999001579A1 (en) | 1999-01-14 |
US6887906B1 (en) | 2005-05-03 |
JP2002510319A (ja) | 2002-04-02 |
US20030040497A1 (en) | 2003-02-27 |
US8691785B2 (en) | 2014-04-08 |
US20040229831A1 (en) | 2004-11-18 |
ATE321882T1 (de) | 2006-04-15 |
EP1012331B1 (de) | 2006-03-29 |
US20130274309A1 (en) | 2013-10-17 |
AU8378698A (en) | 1999-01-25 |
CA2294988A1 (en) | 1999-01-14 |
US6747014B2 (en) | 2004-06-08 |
EP1012331A4 (de) | 2002-06-26 |
AU731909B2 (en) | 2001-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69834038D1 (de) | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre | |
JP2018527013A5 (de) | ||
CN102459302A (zh) | 核酸递送组合物及其使用方法 | |
KR960701077A (ko) | 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates) | |
CY1114620T1 (el) | Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση | |
MXPA05008918A (es) | Sistema de administracion transmucosal de farmacos. | |
JP2007505954A5 (de) | ||
JP2002539265A5 (de) | ||
ATE334657T1 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
DK0799059T3 (da) | Kationiske amfifile forbindelser og plasmider til intracellulær administration af terapeutiske molekyler | |
DE602004031771D1 (de) | Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon | |
ATE234919T1 (de) | Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt | |
AR033042A1 (es) | Terapia de reemplazo hormonal | |
DE69732029D1 (de) | Dna enthaltende impfstoffen | |
ATE241338T1 (de) | Arzneistoffabgabesystem, insbesondere zur verabreichung von androgenen | |
US11268098B2 (en) | Non-aggregating immunostimulatory oligonucleotides | |
MA27474A1 (fr) | Vaccin | |
WO2001098522A3 (en) | Positively-charged peptide nucleic acid analogs with improved properties | |
Joshi et al. | Childhood lichen planus | |
von der Haar et al. | Translation of in vitro-transcribed RNA therapeutics | |
ATE389017T1 (de) | Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) | |
ATE312599T1 (de) | Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten | |
DE60140950D1 (de) | Neuer gentherapeutischer wirkstoff zur behandlung g | |
DE60023285D1 (de) | Gesteigerte abgabe von auf nukleinsäuren basierenden arzneimitteln | |
ATE359764T1 (de) | Durch liposome vermittelte dna verabreichung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |